NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
Clinical Trials
13 trialsNCT03076554 2026-04-07
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04417660 2026-04-07
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05104736 2026-04-07
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03463460 2026-03-23
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07479628 2026-03-18
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07132918 2026-03-11
HEARTS Trial for Thoracic Cancers
University of Wisconsin, Madison
Phase 2 Recruiting
NCT07463313 2026-03-11
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Not yet recruiting
NCT03968315 2026-03-09
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04710628 2026-02-19
PECATI
MedSIR
Phase 2 Completed
NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03295227 2026-01-30
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06248515 2026-01-27
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Georgetown University
Phase 2 Recruiting